It is an exciting time for Batten research! As new research and potential trials are announced it is important that as a community that we understand the typical path research takes from the lab bench to patient bedside. Global Genes has developed a wonderful resource illustrating the drug development journey, the Drug Development Roadmap can be found here. Below is an outline of the path a typical treatment must take to approval. Keep in mind that for rare diseases, like Batten disease, the journey can be a little different because of Food and Drug Administration (FDA) programs that can help speed process up. One such program is the Orphan Drug Act of 1983 which addresses the unique challenges facing rare disease communities by providing incentives to companies that develop treatments for very small patient populations. Other terms you might hear are Accelerated Approval, Priority Review, Fast Track, Breakthrough Therapy, and Pediatric Priority Review Voucher Program.